Abstract
After binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely distributed in both the central and peripheral nervous systems, induces tumor cell proliferation, angiogenesis, and migration of the tumor cells for invasion and metastasis. However, after binding to NK-1 receptors, NK-1 receptor antagonists inhibit the three above mechanisms. In fact, the antiproliferative action exerted by NK-1 receptor antagonists is because they induce cancer cells to die by apoptosis, whereas SP exerts an antiapoptotic effect. Moreover, it is known that NK-1 receptors are overexpressed in tumors and that tumor cells express several isoforms of the NK-1 receptor. All these data suggest that the SP/NK-1 receptor system could play an important role in the development of cancer; that SP may be a universal mitogen in NK-1 receptor-expressing tumor cells, and that NK-1 receptor antagonists could offer a promising therapeutic strategy for the treatment of human cancer, since they act as broad-spectrum antitumor agents. In sum, the NK-1 receptor may be a new and promising target in the treatment of human cancer.
Keywords: NK-1 receptor antagonist, substance P, mitogenesis, neoangiogenesis, metastasis, tumor cells, apoptosis, cancer, chemotherapy
Current Drug Targets
Title: The NK-1 Receptor: A New Target in Cancer Therapy
Volume: 12 Issue: 6
Author(s): Miguel Munoz, Marisa Rosso and Rafael Covenas
Affiliation:
Keywords: NK-1 receptor antagonist, substance P, mitogenesis, neoangiogenesis, metastasis, tumor cells, apoptosis, cancer, chemotherapy
Abstract: After binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely distributed in both the central and peripheral nervous systems, induces tumor cell proliferation, angiogenesis, and migration of the tumor cells for invasion and metastasis. However, after binding to NK-1 receptors, NK-1 receptor antagonists inhibit the three above mechanisms. In fact, the antiproliferative action exerted by NK-1 receptor antagonists is because they induce cancer cells to die by apoptosis, whereas SP exerts an antiapoptotic effect. Moreover, it is known that NK-1 receptors are overexpressed in tumors and that tumor cells express several isoforms of the NK-1 receptor. All these data suggest that the SP/NK-1 receptor system could play an important role in the development of cancer; that SP may be a universal mitogen in NK-1 receptor-expressing tumor cells, and that NK-1 receptor antagonists could offer a promising therapeutic strategy for the treatment of human cancer, since they act as broad-spectrum antitumor agents. In sum, the NK-1 receptor may be a new and promising target in the treatment of human cancer.
Export Options
About this article
Cite this article as:
Munoz Miguel, Rosso Marisa and Covenas Rafael, The NK-1 Receptor: A New Target in Cancer Therapy, Current Drug Targets 2011; 12 (6) . https://dx.doi.org/10.2174/138945011795528796
DOI https://dx.doi.org/10.2174/138945011795528796 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Generation of a Chimeric Plasmin-resistant VEGF165/VEGF183 (132-158) Protein and its Comparative Activity
Protein & Peptide Letters Cancer Nanotechnology: Recent Trends and Developments in Strategies for Targeting Cancer Cells to Improve Cancer Imaging and Treatment
Current Drug Metabolism White Poplar (Populus alba L.) Suspension Cultures as a Model System to Study Apoptosis Induced by Alfalfa Saponins
Anti-Cancer Agents in Medicinal Chemistry Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Post-Translational Control of Sp-Family Transcription Factors
Current Genomics Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Reviews on Recent Clinical Trials Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Autoimmune Neuromuscular Disorders
Current Neuropharmacology CD4+CD25+ T Regulatory Cells and TGF-β in Mucosal Immune System: The Good and the Bad
Current Medicinal Chemistry Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets